Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States
- University of Colorado
Denver, Colorado, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Jan 2013
- Primary completion
- 12 Jul 2016
- Completion
- 12 Jul 2016
- Last update posted
- 22 Aug 2017
- Registered enrollment
- 42
- Registry id
- NCT01783171
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.